



29 April 2019

QUARTERLY REPORT FOR THE QUARTER ENDED 31 MARCH 2019

Bioxyne Limited (ASX Code: BXN) (Bioxyne or the Company) is pleased to report on its activities for the quarter ended 31 March 2019.

Results

Sales revenues for Q3 FY2019 were \$103,438 with a timing delay in PCC[®] wholesale sales to NuSkin. New orders received in April 2019 (~A\$600,000) should be delivered before 30 June 2019, achieving an annual result for PCC sales close to the prior year.

While substantial work has been done in Indonesia on product and sales training, new product registrations are only expected in Q2 calendar 2019 with the delay attributable to disruption caused by recent super elections of Parliament. A return to normal trading conditions is expected with the re-election of the incumbent government and President.

Malaysia remains slow after the recent general election, however product roadshows and a growing distributor network is expected to show improvement in the current quarter.

The successful resolution on a no admission of liabilities basis from both parties in the legal matter with New Image reiterated the independence of distributors in a multi-level direct sales marketing structure.

Business development

Australia

The Company is continuing to review acquisition opportunities with direct selling and product synergy that will allow expansion into Asia.

China

A significant tightening of regulations relating to food products/supplements and the direct selling industry will extend our timeline for direct engagement in this market.

The Company is reviewing opportunities to provide its products through wholesale channels.



Vietnam

The Group's wholesale sales via third party distributors in this country are expected to grow steadily in the months ahead.

The increasing regulatory requirements of direct sales in the markets that we are in, has confirmed the high growth of the sector and its distribution as a mainstream sales channel. The Company is re-aligning its growth strategy to those countries with potential acquisitions of local direct sales companies.

A further order from the wholesale sales channel in the amount of US\$176,000 was received most quarter end and will be delivered in July 2019.

Corporate

Cash on hand as at 31 March 2019 amounted to \$2.48 million.

The New Image legal matter was settled for approximately A\$0.48 in early April 2019.

For more information, please contact:

N H Chua, Managing Director, Bioxyne Limited +61 2 9078 8180

Guy Robertson, Chief Financial Officer +61 2 9078 8180 or +61 407 983 270

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Bioxyne Limited

ABN

97 084 464 193

Quarter ended ("current quarter")

31 March 2019

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	577	1,563
1.2 Payments for		
(a) research and development		(34)
(b) product manufacturing and operating costs	(350)	(688)
(c) advertising and marketing	(23)	(68)
(d) leased assets		
(e) staff costs	(232)	(580)
(f) administration and corporate costs	(41)	(767)
1.3 Dividends received (see note 3)		
1.4 Interest received	29	42
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Government grants and tax incentives R&D Tax offset		
1.8 Other (legal fees)	(100)	(232)
1.9 Net cash from / (used in) operating activities	(140)	(762)
2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment	-	(21)
(b) businesses (see item 10)	(39)	(132)
(c) investments		

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
(d) intellectual property		
(e) other non-current assets		
2.2 Proceeds from disposal of:		
(a) property, plant and equipment		
(b) businesses (see item 10)		
(c) investments		
(d) intellectual property		
(e) other non-current assets		
2.3 Cash flows from loans to other entities		
2.4 Dividends received (see note 3)		
2.5 Other		
2.6 Net cash from / (used in) investing activities	(39)	(153)

3. Cash flows from financing activities		
3.1 Proceeds from issues of shares		
3.2 Proceeds from issue of convertible notes		
3.3 Proceeds from exercise of share options	-	
3.4 Transaction costs related to issues of shares, convertible notes or options		
3.5 Proceeds from borrowings		
3.6 Repayment of borrowings		
3.7 Transaction costs related to loans and borrowings		
3.8 Dividends paid		
3.9 Other (provide details if material)		
3.10 Net cash from / (used in) financing activities		

4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of quarter/year to date	2,650	3,310
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(334)	(622)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	(39)	(153)
4.4 Net cash from / (used in) financing activities (item 3.10 above)		

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
4.5	Effect of movement in exchange rates on cash held	(3)	73
4.6	Cash and cash equivalents at end of quarter	2,468	2,468

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,846	921
5.2	Call deposits	622	1,729
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	2,468	2,650

6. Payments to directors of the entity and their associates

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

**Current quarter
\$A'000**

107

Directors salaries and fees.

7. Payments to related entities of the entity and their associates

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

**Current quarter
\$A'000**

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities		
8.2 Credit standby arrangements		
8.3 Other (please specify)		
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

9. Estimated cash outflows for next quarter	\$A'000
9.1 Research and development	-
9.2 Product manufacturing and operating costs	150
9.3 Advertising and marketing	50
9.4 Leased assets	
9.5 Staff costs	200
9.6 Administration and corporate costs	300
9.7 Other (provide details if material)	
9.8 Total estimated cash outflows	700

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity		
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of businesses		

